We often talk about innovation in terms of science and technology, but in today’s healthcare ecosystem, it’s just as important to innovate on the business side of things. That’s what the $250 million Harrington Project for Discovery & Development, a national initiative based at University Hospitals Case Medical Center, is trying to do. It comprises […]
Updated to add comments from Shah Baiju Shah, for years a central public face in Greater Cleveland’s push to build its life science sector, is leaving his post in the region’s key trade group to lead a biotech commercialization project in the city. Shah, the founder and longtime CEO of BioEnterprise, will join BioMotiv, the […]
Home health equipment manufacturer Invacare (NYSE: IVC) has added the president and CEO of Cleveland nonprofit BioEnterprise to its board. Baiju Shah will join Elyria, Ohio-based Invacare’s board of directors, according to a company statement. BioEnterprise was started in 2002 to help Northeast Ohio biomedical companies grow their businesses. Prior to BioEnterprise, Shah worked with […]
Cleveland is already well-known for its high quality medical care. But its reputation is growing elsewhere. Some of the nation’s best and brightest are flocking to University Circle to be on the cutting edge of the biotech innovation. Channel 3’s Maureen Kyle continues our “Brain Gain” series with a look at how this could be […]
When it comes to keeping smiles on the faces of Ohio's medical industry leaders, Governor-elect John Kasich's predecessor did him a big favor. It's called Ohio Third Frontier.
Ask most people touched by the Ohio Third Frontier project whether it ought to be renewed and you'll get a resounding "Yes!" A tougher question: How much money should the state borrow to extend the program beyond fiscal 2012, when its term ends? Ohio legislators will grapple with this question as they try to meet a Feb. 3 deadline to get the renewal on the May 4 ballot.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Biomedical companies with compelling technologies could win millions of dollars in investments this year despite the worst gloom in financial markets since the Great Depression.
